Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha

被引：23
|
作者：
Verma, Dushyant [1 ]
Kantarjian, Hagop [1 ]
Jain, Nitin [1 ]
Cortes, Jorge [1 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
LEUKEMIA & LYMPHOMA | 2008年 / 49卷 / 07期
关键词：
D O I：
10.1080/10428190802043903
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1399 / 1402
页数：4
相关论文
共 50 条
  • [1] Sustained Complete Molecular Remission after Imatinib Discontinuation in Children with Chronic Myeloid Leukemia
    Moser, Olga
    Krumbholz, Manuela
    Thiede, Christian
    Tauer, Josephine T.
    Janz, Indra
    Lauten, Melchior
    Dilloo, Dagmar
    Metzler, Markus
    Suttorp, Meinolf
    PEDIATRIC BLOOD & CANCER, 2014, 61 (11) : 2080 - 2082
  • [2] Sustained Molecular Response with Maintenance Dose of Interferon Alfa After Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia
    Usuki, Kensuke
    Yusa, Nozomi
    Hangaishi, Akira
    Sekine, Rieko
    Suzuki, Kenshi
    Kimura, Shinya
    Tojo, Arinobu
    BLOOD, 2012, 120 (21)
  • [3] Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy
    Seiichi Okabe
    Tetsuzo Tauchi
    Yuko Ishii
    Daigo Akahane
    Kousuke Nunoda
    Seiko Honda
    Tomoiku Takaku
    Kazuma Ohyashiki
    International Journal of Hematology, 2007, 85 : 173 - 174
  • [4] Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Ishii, Yuko
    Akahane, Daigo
    Nunoda, Kousuke
    Honda, Seiko
    Takaku, Tomoiku
    Ohyashiki, Kazuma
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2007, 85 (02) : 173 - 174
  • [5] Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia
    Ghanima, W
    Kahrs, J
    Dahl, TG
    Tjonnfjord, GE
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2004, 72 (06) : 441 - 443
  • [6] Treatment with Interferon alpha prior to discontinuation of Imatinib in patients with chronic myeloid leukemia
    Hardan, Izhar
    Stanevsky, Anfisa
    Volchek, Yuliya
    Tohami, Tali
    Amariglio, Ninette
    Trakhtenbrot, Luba
    Koren-Michowitz, Maya
    Shimoni, Avichai
    Nagler, Arnon
    CYTOKINE, 2012, 57 (02) : 290 - 293
  • [7] Discontinuation of Imatinib Therapy in Chronic Myeloid Leukemia Patients with Sustained Complete Molecular Response4.5(CMR4.5)
    Goh, Hyun-Gyung
    Choi, Soo-Young
    Bang, Ju-Hee
    Kim, Soo-Hyun
    Jang, Eun-Jung
    Kim, Dongho
    Byeun, Ji-Young
    Park, Joon Seong
    Kim, Hyeoung-Joon
    Kim, Hawk
    Kim, Dong-Wook
    BLOOD, 2011, 118 (21) : 1189 - 1189
  • [8] Discontinuation of Imatinib Therapy After Achieving a Molecular Response in Chronic Myeloid Leukemia Patients
    Mahon, Francois-Xavier
    Rea, Delphine
    Guilhot, Francois
    Huguet, Francoise
    Nicolini, Franck Emmanuel
    Legros, Laurence
    Charbonnier, Aude
    Guerci, Agnes
    Varet, Bruno R.
    Etienne, Gabriel
    Aton, Emilie
    Reiffers, Josy
    Rousselot, Philippe
    BLOOD, 2009, 114 (22) : 353 - 353
  • [9] DISCONTINUATION OF IMATINIB (IM) IN PEDIATRIC CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH SUSTAINED COMPLETE MOLECULAR REMISSION (CMR)
    Giona, F.
    De Vellis, A.
    Moleti, M.
    Gottardi, E.
    Rea, M.
    Nanni, M.
    Testi, A.
    Diverio, D.
    Saglio, G.
    Foa, R.
    HAEMATOLOGICA, 2013, 98 : 65 - 65
  • [10] Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response
    Latagliata, Roberto
    Romano, Angela
    Mancini, Marco
    Breccia, Massimo
    Carmosino, Ida
    Vozella, Federico
    Montagna, Chiara
    Volpicelli, Paola
    De Angelis, Federico
    Petrucci, Luigi
    Serrao, Alessandra
    Molica, Matteo
    Salaroli, Adriano
    Diverio, Daniela
    Alimena, Giuliana
    LEUKEMIA & LYMPHOMA, 2016, 57 (01) : 99 - 102
12345